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Gain- and Loss-of-Function Lyn Mutant Mice
Define a Critical Inhibitory Role for Lyn
in the Myeloid Lineage
mic lymphomas (Abraham et al., 1991) or mammary
gland neoplasia, respectively (Webster et al., 1995). Sim-
ilarly, transgenic mice expressing v-Src kinase under
control of glial fibrillary acidic protein gene regulatory
elements develop astrocytomas (Weissenberger et al.,
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1997), while H-2K promoter BlkY495F mutant transgenicMelbourne Tumor Biology Branch
mice develop lymphoid tumors (Malek et al., 1998).Royal Melbourne Hospital
These studies, coupled with the observation that SrcMelbourne, Victoria 3050
is essential for mammary tumor development in Neu2 Melbourne Pathology
transgenic mice, have contributed to the prevailing viewRoyal Women’s Hospital
that Src family kinases are participants in signaling path-Carlton, Victoria 3052
ways governing specific aspects of oncogenesis (Guy3 Victorian Breast Cancer Research Consortium
et al., 1994).University of Melbourne
Although the Lyn tyrosine kinase has been reported toParkville, Victoria 3050
associate with many hematopoietic receptors includingAustralia
the BCR, FcRI, CD14, and c-Kit among others (reviewed
by Corey and Anderson, 1999), to date, analysis of Lyn/
mice has focused on a phenotype largely limited to theSummary
B lymphoid compartment (Hibbs et al., 1995a; Nishizumi
et al., 1995, 1998; Chan et al., 1997). Interestingly, theseTo investigate the role of the Lyn kinase in establishing
studies have revealed that although Lyn contributes tosignaling thresholds in hematopoietic cells, a gain-
BCR-induced tyrosine phosphorylation, it has an indis-of-function mutation analogous to the Src Y527F-acti-
pensable role in phosphorylating specific tyrosine resi-vating mutation was introduced into the Lyn gene.
dues contained within immunoreceptor tyrosine-basedIntriguingly, although Lyn is widely expressed within
inhibitory motifs (ITIM) in the cytoplasmic domains ofthe hematopoietic system, these mice displayed no
inhibitory receptors such as CD22 (Smith et al., 1998;propensity toward hematological malignancy. By con-
Cornall et al., 1998), PIR-B (Maeda et al., 1998; Ho et al.,trast, analysis of aging cohorts of both loss- and gain-
1999), and FcRIIB (Chan et al., 1997, 1998; Nishizumi etof-function Lyn mutant mice revealed that Lyn/ mice
al., 1998). Consequently, B cells lacking Lyn fail to recruitdevelop splenomegaly, increased numbers of myeloid
the PTP SHP-1 and the SH2-containing 5-inositol phos-progenitors, and monocyte/macrophage (Mφ) tumors.
phatase (SHIP-1) to the plasma membrane in responseBiochemical analysis of cells from these mutants re-
to appropriate stimuli. These signaling deficiencies arevealed that Lyn is essential in establishing ITIM-depen-
thought to underpin the Lyn/ mouse B lymphoid phe-dent inhibitory signaling and for activation of specific
notype which includes reduced levels of mature B cells,protein tyrosine phosphatases within myeloid cells.
hyper-IgM, hyperresponsive BCR-dependent prolifera-Loss of such inhibitory signaling may predispose mice
tion, diminished FcRIIB1-dependent signal inhibition,lacking this putative protooncogene to tumorigenesis.
and production of autoreactive antibodies culminating
in immune complex deposition in the kidneys (Hibbs etIntroduction
al., 1995a; Nishizumi et al., 1995, 1998; Chan et al., 1997).
In studies aimed at investigating the role of Lyn in
A mutated version of c-Src, the prototypic member of
murine hematopoietic system development and directly
the Src family of protooncogenes, is the dominantly
assessing its positive versus negative signaling roles, a
acting oncogene encoded by the Rous sarcoma virus gain-of-function mutation was introduced into the Lyn
(Stehelin et al., 1976; Brugge and Erikson, 1977). Mu- locus. The gain-of-function knockin mutant, like the nat-
tated versions of c-Src lacking a carboxy-terminal tyro- urally occurring RSV Src mutant, lacks a critical tyrosine
sine phosphorylation site have the capacity to transform phosphorylation site at the C terminus required for nega-
fibroblasts and illicit tumors in immunocompromised tive regulation of kinase activity, and is thus constitu-
hosts. Similarly, gain-of-function mutants of other Src tively active.
family kinases including Fyn, Yes, Fgr, Lck, and Hck Our studies of aged Lyn mutant mice (both loss- and
possess the ability to transform cell lines either when gain-of-function) reveal that Lyn-deficient mice develop
introduced into such cells alone (reviewed by Brown a dramatic increase in myeloid progenitors, splenomeg-
and Cooper, 1996) or in combination with proteins such aly, and disseminated monocyte/Mφ tumors while Lyn
as HIV nef (Briggs et al., 1997; Moarefi et al., 1997). gain-of-function mice are tumor free. Overall, this study
Studies using standard transgenic technology have demonstrates that loss of the Lyn kinase leads to tu-
demonstrated that deregulated Src family kinase activity mor development and highlights a critical role for this
and expression can lead to tumorigenesis. For example, tyrosine kinase in establishing phosphatase-dependent
p56LckY505F and p60SrcY527F transgenic mice develop thy- inhibitory signaling pathways in the monocyte/Mφ com-
partment of the hematopoietic system. This data estab-
lishes a new paradigm for the role of a Src family member4 Correspondence: margaret.hibbs@ludwig.edu.au
5 Deceased. in tumorigenesis.
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Figure 1. Generation of the Lyn Gain-of-
Function (Lynup) Mutant Mouse
(A) Lyn kinase protein structure and targeting
vector for modification of the Lyn gene. The
3 end of the mouse Lyn locus, the targeting
vector, and recombinant lyn knockin allele are
shown. Exon 13 containing Y508 is depicted
as a box.
(B) Total RNA from Lyn/, Lyn/up, and Lynup/up
BMMφs was probed with the Lyn cDNA (up-
per panel). The predicted size of the wild-type
(w.t.) Lyn (3.4 kb) and the IRES-neo cassette
containing Lyn mutant (mut.) (4.8 kb) mRNAs
are indicated. A -actin probe was used to
assess loading (lower panel).
(C) Total cell lysates (TCL) from BMMφs de-
rived from mice of the indicated genotypes
were blotted with anti-Lyn Abs. The blot was
then stripped and reblotted with anti-SHP-1
or anti-Hck Abs to ensure equal protein load-
ing. Arrows indicate the positions of the p56
and p53 Lyn isoforms, or those of SHP-1 and
Hck.
(D) BMMφ TCLs shown in Figure 1C were
stripped and blotted with anti-PY Abs. Arrows
indicate proteins exhibiting enhanced anti-
PY immunoreactivity in Lynup/up and Lyn/up
samples.
(E) Assessment of Lyn kinase activity. Lyn
kinase was precipitated from lysates con-
taining equalized amounts of Lyn (upper
panel, with densitometry values) and sub-
jected to an immune complex kinase assay
in the presence of recombinant PTP domain
2 substrate.
(F) BMMφs from the indicated mice were
treated with pervanadate for the times shown
and TCLs were blotted with anti-PY Abs.
Results Lyn gene (exon 13) along with an IRES neomycin cas-
sette (Figure 1A). A Northern blot of total RNA isolated
from bone marrow macrophages (BMMφs) confirmedGeneration of LynY508F (Lynup) Gain-of-Function
Mutant Mice expression of the bicistronic message in both Lynup/up
and Lyn/up cells (Figure 1B). Immunoblots of total cellA gain-of-function mutation in Lyn was introduced into
the mouse germline by homologous recombination in lysates (TCL) from BMMφs with Lyn-specific antibodies
(Abs) established Lynup protein expression. However,ES cells. Site-directed mutagenesis was used to intro-
duce the Tyr-to-Phe activating mutation at residue 508 reduced levels of Lynup protein, and in particular the p56
isoform, were detected in Lynup/up-derived BMMφs and(LynY508F, hereafter referred to as Lynup) into the murine
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other primary cell types (Figure 1C and data not shown).
Reduced levels of Lynup protein were observed regard-
less of the detergent used to produce cell lysates. Immu-
noblotting with SHP-1- and Hck-specific antisera re-
vealed similar levels of both of these proteins in the
BMMφs (Figure 1C, panels 2 and 3). Our preliminary
data suggest that the activated form of Lyn, like other
activated Src kinase mutants, is subject to ubiquitin-
dependent degradation (data not shown; Oda et al.,
1999; Hakak and Martin, 1999; Harris et al., 1999). De-
spite reduced levels of Lynup protein, increased levels
of overall tyrosine phosphorylation were observed fol-
lowing antiphosphotyrosine (PY) immunoblotting of
BMMφ TCLs (Figure 1D). Moreover, kinase assays per-
formed on equalized levels of Lyn protein revealed a 2-
to 3-fold increase in the specific activity of the Lynup
protein (Figure 1E).
It is well established that the activity of tyrosine ki-
nases and their substrates is tightly regulated by the
opposing activity of a large family of PTPs. To assess
the contribution of PTP activity to the relatively modest
increase in overall tyrosine phosphorylation in Lynup-
derived cells, we investigated the sensitivity of Lynup
mutant cells to the PTP inhibitor pervanadate. BMMφs
were treated with modified pervanadate (100 M Vn;
2 M H2O2) and levels of tyrosine phosphorylation in
TCLs were analyzed (Figure 1F). Both the Lynup/up and
Lyn/up cells exhibited dramatically enhanced levels of
tyrosine phosphorylation following pervanadate treat-
ment. By contrast, both Lyn/ and Lyn/ BMMφs were
apparently unaffected by this dose of drug. These re-
sults, combined with the elevated levels of anti-PY im-
munoreactivity detected in lysates from Lynup/up and
Lyn/up BMMφs, confirm that the Y508F substitution in-
Figure 2. Lyn/ Mice Develop Severe Splenomegaly and Dissemin-troduced into the Lyn gene results in a gain-of-function
ated Mφ Tumors that Can Be Transferred into SCID Mouse Recip-Lyn kinase mutant.
ients
(A) Spleens from age-matched 18-month-old Lyn/ (0.08 g) and
Age-Dependent Development of Splenomegaly Lyn/ (3.21 g) mice.
and Disseminated Myelomonocytic Cells (B) An example of tumors on the ears of a Lyn/ mouse.
in Lyn/ but Not Lynup/up Mice (C) A mass of cells on the tail of a Lyn/ mouse.
(D) Transmission EM of cells comprising the tail mass in (C), originalTo investigate Lyn’s role in signal transduction/inhibition
magnification 5.0 K. The scale bar represents 10 m.and to directly assess the oncogenic potential of the
(E) Single-cell suspensions from spleens from Lyn/ mice exhibitingLyn gain-of-function mutant, a cohort of Lyn/, Lyn/,
various degrees of splenomegaly were injected into 13 female SCID
and Lynup/up mice was investigated for age-dependent mouse recipients and tumor latency was assessed. Spleen cell sus-
differences in various hematopoietic parameters (see pensions from two tumor-bearing primary SCID mice (seeded with
supplemental table at http://www.immunity.com/cgi/ cells from Lyn/ donor #1) were injected into a total of seven sec-
ondary SCID mouse recipients and tumor latency was determined.content/full/15/4/603/DC1) and the cellular composition
The asterisk represents those found dead.of spleen and bone marrow (BM). As previously ob-
served, Lyn/ mice developed an age-dependent in-
crease in spleen weight (Supplemental Table S1; Nishi-
zumi et al., 1995; Chan et al., 1997), a phenotype that counts for 6- to 8-week-old mice were: Lyn/, 609 	
207/l; Lynup/up, 1089 	 242/l (n 
 12); and for 52- tois at least partially dependent on the Btk kinase (Take-
shita et al., 1998; Satterthwaite et al., 1998). By contrast, 58-week-old mice: Lyn/, 1262 	 434/l; Lynup/up,
2540 	 1050/l (n 
 8).Lynup/up mouse spleen weights were modestly lower than
those of Lyn/ mice (due to specific Lynup/up B-lymphoid Splenomegaly became severe (0.5 g) in approxi-
mately 20% of Lyn/ mice greater than 1 year of agedifferences; our unpublished data). We also observed a
decrease in platelet numbers in Lyn/ mice which be- with partial or almost complete replacement of the red
and white pulp by atypical myelomonocytic cells oftencame more pronounced with age (Supplemental Table
S1). Flow cytometry analyses of Lynup/up blood, spleen, admixed with centers of extramedullary hematopoiesis
(EMH; Figures 2A and 3A). Enlargement of the spleensand BM were unremarkable in terms of the myeloid com-
partment with the exception of an increase in the num- of Lyn/ mice was also frequently associated with dis-
seminated accumulations of myelomonocytic cells inbers of neutrophils in spleen and peripheral blood of
Lynup/up mice. For example, peripheral blood neutrophil the liver and lymph nodes. These cells were also com-
Immunity
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Figure 3. Histological and Immunohistochemical Analysis of Lyn/ Mice, Tumor-Bearing SCID, and Lyn//MT/MT Mice
(A–D) Histological analysis of tumor-bearing Lyn/ mice. A Mφ/histiocytic tumor in the spleen of a Lyn/ mouse (A). Mφ/histiocytic tumors
in the kidney (B) and BM (C) of SCID mouse recipients of Lyn/ spleen-derived donor cells. Expansion of Mφ/histiocytic tumor in the BM of
a Lyn//MT/MT mouse (D).
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monly observed in aged Lyn/ mice with mild spleno- we produced Lyn//MT/MT mice. Despite the lack
of mature B cells due to disruption of the  chain trans-megaly. Accumulation of such cells was often observed
in lungs, BM, connective tissue, ovaries, pancreas, membrane domain-encoding exon, these double mutant
mice developed tumors indistinguishable from Lyn/bowel, and kidneys, with some cells exhibiting atypical
mitoses, highly suggestive of malignancy (data not mice as evidenced by an expansion of Mφ/histiocytes
in the Lyn//MT/MT femur shown (Figure 3D).shown). Intriguingly, older Lyn/ mice sporadically de-
veloped large aggregates of myelomonocytic cells on
the tail, ears, and legs (Figures 2B and 2C). These cells Characterization of Lyn/ Mouse Mφ Tumors
Lyn/ tumor cells were characterized by immunohisto-were phenotypically similar to those disseminated
throughout other organs. Transmission electron micros- chemistry with monoclonal antibodies (mAbs) specific
for granulocyte, Mφ, or lymphocyte cell surface mark-copy (EM) of these masses revealed cells with a mean
diameter of 45.3	 4.8 m that were rich in mitochondria ers. Tumor cells stained strongly with mAbs against
the myeloid marker Mac-1 (Figure 3G) and the moreand lysosomes (Figure 2D). Some cells in the fields also
exhibited pseudopodia. Notably absent were any cells restricted Mφ marker F4/80 (Figure 3H), and to a lesser
degree with Abs toward the granulocytic/monocyticindicative of infection.
marker Ly6G (Gr-1; Figure 3I). The sections did not stain
with isotype control Abs (Figure 3E) or with B or T cell-Transplantability of Monocyte/Mφ Tumors into
SCID Mice and Tumor Development specific markers such as B220 (Figure 3F), CD19, or
Thy-1 (data not shown). Immunohistochemistry of tu-in Lyn//MT/MT Mice
We assessed the tumorigenic potential of the myelo- mor-bearing SCID mice confirmed the myeloid nature
of the transplanted tumor (data not shown). Both B andmonocytic population in Lyn/ mice by injecting splenic
cells from Lyn/ mice into SCID mice (Figure 2E). Donor T cell-specific staining of tumor tissue and FACS analy-
sis of cells obtained from such tissues failed to detectcells derived from five Lyn/ mice exhibiting spleno-
megaly were injected into 13 female SCID mice. All recip- significant numbers of either cell type. Similarly, immu-
nohistochemical analysis of sections of microdissectedients (except one that was found dead) developed Mφ
tumors with latencies ranging from 5 to 29 weeks and tumors associated with the spine and mesenteric lymph
nodes of a Lyn//MT/MT mouse, like those of Lyn/developed splenomegaly (0.14–1.7 g). Furthermore,
when single-cell suspensions of tumor-containing spleens mice, stained with mAbs specific for Mac-1 and F4/80
(Figures 3K and 3L), but not with isotype control (Figurefrom two primary SCID recipients seeded with cells from
Lyn/ donor number 1 were injected into a total of seven 3J) or B220 and Thy-1 mAbs (data not shown).
Ex vivo analysis of these cells provided further evi-secondary SCID mice, six of these mice developed tu-
mors with a similar latency to the primary recipients. dence of the monocyte/Mφ origin of the tumor cells.
Tumor cells prepared from the spine and mesentericSpleen weights of these recipients ranged from 0.21 to
0.83 g. lymph node of a Lyn//MT/MT mouse and grown ex
vivo stained with Mφ markers (Mac-1, c-fmslow, andDetailed histological examination of injected SCID
mice revealed tumor in the spleens of all but two recipi- F4/80), lacked B cell marker expression (CD19), and
were dependent on CSF-1 for their growth in vitro (Figureents (12/14). Tumor deposits were also observed in liver
(13/14), lungs (8/14), perinephric fat (8/14), BM (11/14), 3M). Taken together, the transmission EM, general
histology, immunohistochemistry, FACS analysis, andand lymph nodes. A section of a recipient SCID mouse
illustrates monocytoid/histiocytic expansions in kidney CSF-1 dependence in vitro are supportive of a Mφ (or
histiocytic) classification for these cells.and BM (Figures 3B and 3C). Tumor in the BM varied
from almost complete replacement to small focal depos-
its. Confirmation that these cells were derived from do- Increased Myeloid Progenitors in Spleen
and Peripheral Blood of Lyn/ Micenor Lyn/ mice was obtained by PCR to detect the Lyn
knockout allele (data not shown). The development of disseminated Mφ tumors in older
Lyn/ mice and their growth in SCID mice prompted usLyn/ mice have high serum IgM and self-reactive
Abs that with age result in a severe kidney pathology to investigate whether deregulated myelopoiesis might
be a preexisting subpathological condition in younger(Hibbs et al., 1995a; Nishizumi et al., 1995). Others have
suggested that Lyn/ mice also develop an expansion Lyn/ mice. We assessed numbers of myeloid progeni-
tors in the spleen, BM, and peripheral blood of Lyn/,of Mac1/CD5 B1-B cells in lymphoid organs (Chan
et al., 1997) and an atypical splenic B cell population Lyn/, and Lynup/up mice. Both splenic and peripheral
blood M-CFCs were dramatically enhanced in the bloodcontaining cytoplasmic Ig (Nishizumi et al., 1995). To
investigate whether tumor development was dependent (8 weeks) and spleen (16 weeks) of Lyn/ mice (Figures
4A and 4B). The spleens of Lyn/ mice also exhibitedon B cell-dependent autoimmunity in Lyn/ mice and
to preclude the possibility of a B cell tumor classification, enhanced CFU-GM, CFU-G, CFU-IL3, and CFU-SCF col-
(E–L) Immunohistochemical analysis of Lyn/ tumors. Cryostat sections from a tumor on the ear of a Lyn/ mouse were stained with isotype
control (E); B220 (F); Mac-1 (G); F4/80 (H); and Gr-1 (I). An enlarged mesenteric lymph node mass from a Lyn//MT/MT mouse was stained
with isotype control (J); Mac-1 (K); and F4/80 (L).
(M) Microdissected tumors associated with the spine and mesenteric lymph node from the same Lyn//MT/MT mouse analyzed in (J–L)
were passed through a mesh, and single-cell suspensions were analyzed by FACS for cell surface marker expression (left and middle panels).
Cells were grown for 3 or 8 days in either the presence or absence of CSF-1 and counted (right panel).
Immunity
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Figure 4. Lyn/ Mice Possess Increased Numbers of Myeloid Progenitors, Splenic Myeloid Cells, and Peripheral Blood Monocytes
(A) Splenic progenitors in Lyn/ (closed bars) and Lyn/ mice (open bars) were assessed by in vitro semisolid agar assays in the presence
of the indicated cytokines. Numbers shown are the mean 	 standard error of the mean (SEM) for two groups of three 16-week-old mice in
two separate experiments.
(B) Peripheral blood progenitor populations were determined in Lyn/ (open bars), Lyn/ (closed bars), and Lynup/up (hatched bars) mice as
above. Values represent the mean 	 SEM of triplicate determinations for at least two mice per group.
(C) Peripheral blood progenitors in Lyn/, Lyn/, and Mev/Mev mice were assessed as in (B).
(D) FACS analysis of peripheral blood and splenic single-cell suspensions from 35-week-old Lyn/ and Lyn/ mice. Spleen weights were
Lyn/, 0.086 g; Lyn/1, 0.534 g; and Lyn/2, 0.486 g. WBC counts were similar: Lyn/, 8.4  106/ml; Lyn/1, 8.4  106/ml; and Lyn/2,
8.0  106/ml.
onies as compared to age-matched Lyn/ mice (Figure signal-inhibitory proteins. For example, Mev/Mev and
SHIP-1/ mutant mice both develop splenomegaly and4A). By contrast, the frequencies of BM CFU-M and
CFU-GM progenitor populations were similar among the EMH, and have elevated progenitor numbers (Van Zant
and Shultz, 1989; Helgason et al., 1998; Liu et al., 1999).genotypes (data not shown). Peripheral blood progenitor
numbers in Lynup/up mice were similar to those of Lyn/ Comparisons between age-matched 7- to 9-week-old
Mev/Mev and Lyn/ mice showed a dramatic enhance-mice (Figure 4B).
Some features of the phenotype of Lyn/ mice are ment in CFU-M in the peripheral blood of both mouse
mutants (Figure 4C). Strikingly, Lyn/ mice exhibitedsimilar to those exhibited by mice deficient in specific
A Role for the Lyn Kinase in Tumor Suppression
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Figure 5. Lyn/ BMMφs Are Hypersensitive
to CSF-1 and GM-CSF
(A and B) Lyn/, Lyn/, and Lynup/up BMMφ
cell numbers were assessed in either CSF-1
(A) or GM-CSF (B). Relative cell numbers were
determined by MTT assay. Each point repre-
sents the mean 	 standard deviation (SD) of
triplicate wells.
(C) The relative survival of BMMφs from
Lyn/ (open symbols) and Lyn/ (closed
symbols) mice was assessed at 16, 24, and
48 hr in either the absence of added factor
(open square/closed square), 2 ng/ml GM-
CSF (open circle/closed circle), or 0.02 ng/
ml GM-CSF (open triangle/closed triangle).
Points represent the mean 	 SD of duplicate
wells.
(D) BMMφ survival in the absence of growth
factor at 24 and 48 hr. Relative cell numbers
were assessed by MTT assay (Lyn/, open
bars; Lyn/, closed bars; Lynup/up, hatched
bars). Assays were performed in quadrupli-
cate and values represent the mean 	 SD.
greater numbers of peripheral blood Mφ progenitors withdrawal-induced apoptosis (Berg et al., 1999). How-
ever, Lyn/ BMMφs were only modestly less suscepti-than did Mev/Mev mice (Figure 4C). Enhanced myeloid
progenitors were also observed in the presence of IL-3 ble to apoptosis induced by cytokine withdrawal or sub-
optimal doses of GM-CSF (Figures 5C and 5D) andand GM-CSF in both Lyn/ and Mev/Mev mice.
In keeping with the observed increase in splenic and CSF-1 (data not shown). No difference between Lyn/
and Lynup/up cells was observed in these assays (Figureperipheral blood CFU-M and CFU-GM progenitor num-
bers, FACS analysis of spleen and peripheral blood of 5D and data not shown). Together, these results show
that Mφs from Lyn/ mice are hyperresponsive to cyto-35-week-old Lyn/ mice detected increased propor-
tions of neutrophils (Mac-1/Gr-1) and Mφs (Mac-1/ kines and subtly resistant to cytokine withdrawal-
induced apoptosis.F4/80) in the spleens, and increased numbers of mono-
cytes in the peripheral blood of Lyn/ mice (Figure 4D).
We were unable to detect any evidence for increased Lyn-Dependent Regulation of SHP-1/SHIP-1,
and SHP-1 and SHP-2 Association with Specificnumbers of either conventional or B1-B cells in the
spleen (Figure 4D, B220/CD5 profiles) or peripheral ITIM-Bearing Receptors within Mφs
The development of Mφ tumors and elevated Mφ pro-blood (Figure 4D, B220/IgM profiles) of Lyn/ mice. In-
deed, as we have reported previously, levels of mature genitors in Lyn/ mice, coupled with the phenotypic
similarities of Lyn/, Mev/Mev, and SHIP-1/ mice, ledB cells were reduced in Lyn/ mice (Hibbs et al., 1995a).
us to suspect that Lyn might be critical for phosphatase-
dependent inhibitory signaling in myeloid cells. In addi-Enhanced Sensitivity of Lyn/ BMMφs to CSF-1
and GM-CSF tion, elevated tyrosine phosphorylation levels in specific
proteins were consistently observed in TCLs derivedThe dramatic increase in Mφprogenitors and accumula-
tion of Mφ tumors in Lyn/ mice led us to hypothesize from Lyn/ BMMφs suggestive of reduced phospha-
tase activity in these cells (Figure 1D). To investigatethat Lyn/ Mφ and/or their precursors might be hyper-
responsive to cytokines and/or resistant to apoptosis. the role of Lyn in phosphatase regulation, SHP-1 and
SHIP-1 were precipitated from BMMφ and peripheralPrevious reports have shown that Mφs derived from
motheaten mice are hyperresponsive to GM-CSF and blood-derived Mφ lysates (PBDMφs) and assessed for
differential tyrosine phosphorylation and/or associa-CSF-1 due to lack of inhibition normally exerted by the
PTP SHP-1 on cytokine-dependent signal transduction tions with other proteins. Both SHP-1 and SHIP-1 exhib-
ited elevated levels of tyrosine phosphorylation in Lynup/up-(Chen et al., 1996; Jiao et al., 1997). To investigate
whether Lyn might also have an essential inhibitory sig- derived BMMφs, and were correspondingly hypotyrosine
phosphorylated in Lyn/ cells (Figure 6A, upper left andnaling role in Mφ, we compared the CSF-1 and GM-
CSF sensitivity of BMMφs from Lyn/, Lyn/, and upper right panels). Thus, these results demonstrate that
the Lyn kinase regulates the tyrosine phosphorylationLynup/up mice. Although Lyn/ and Lynup/up cells showed
similar cytokine dose responses, Lyn/ cells appeared status of SHP-1 and SHIP-1 in primary cells, an obser-
vation consistent with in vitro and exogenous expres-to be moderately more sensitive to both CSF-1 and GM-
CSF (Figures 5A and 5B). Others have demonstrated sion studies (Yoshida et al., 1999; Phee et al., 2000). In
Lynup/up-derived BMMφs, SHP-1 coprecipitated a tyro-that Me/Me BMMφs are profoundly resistant to cytokine
Immunity
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Figure 6. Lyn-Dependent Regulation of SHP-1/SHIP-1 Tyrosine Phosphorylation and Phosphatase Association with ITIM-Bearing Inhibitory
Receptors
(A) SHP-1 (upper left panel) and SHIP-1 (upper right panel) were precipitated from Lyn/, Lyn/, Lynup/up, and Lyn/up BMMφ lysates and
blotted with anti-PY, anti-SHP-1, or anti-SHIP-1 Abs. Arrows indicate the positions of SHP-1 and SHIP-1.
(B) SHP-2 was precipitated from BMMφ lysates and blotted with anti-PY (upper panel) or anti-SHP-2 Abs (lower panel).
(C) Lysates of BMMφs from control or Lyn mutant mice were incubated with purified fusion proteins containing the tandem SH2 domains of
SHP-2 fused to GST or GST alone. Precipitates were then blotted with either anti-PY (upper panel) or anti-GST Abs (lower panel).
(D) SIRP (left panels) and PIR-B (right panels) were precipitated from Lyn/, Lyn/, and Lynup/up BMMφ lysates and blotted with the Abs
indicated. Lysates were also subject to normal rabbit serum (NRS) precipitations and blotted with the indicated Abs.
(E) 293T cells were cotransfected with SIRP (left panels) or PIR-B (right panels) together with either control vector (Ctr.) or expression vectors
containing the wild-type or Y508F mutant form of Lyn. SIRP and PIR-B were then precipitated and blotted with anti-PY, SIRP, or PIR-B
Abs.
(F) 293T cells were transfected with SHP-1 and SIRP together with the indicated expression vectors. Cells stimulated with CSF-1 (100 ng/
ml) are indicated by a () symbol. SHP-1 was precipitated from lysates of the transfected cells and blotted with the indicated Abs. SIRP
protein levels in TCLs are shown in an anti-SIRP blot (bottom panel).
(G) 293T cells were transfected with the plasmids outlined and SHP-2 was precipitated from lysates of these cells and blotted with anti-PIR-B,
SIRP, or SHP-2 Abs.
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sine-phosphorylated complex of proteins of 130 kDa Differential Recruitment of SHP-1 and SHP-2
(Figure 6A, upper left panel). By contrast, in Lyn/ cells, to the Plasma Membrane in Lyn/
both the tyrosine phosphorylation of SHP-1 and the and Lynup/up BMMφs
phosphorylation/association of the pp130 kDa complex The ability of SHP-1 and SHP-2 to translocate from the
were significantly reduced (Figure 6A). Immunoprecipi- cytoplasm to the plasma membrane is critical in terms
tates of SHP-2 exhibited a similar pattern of coprecipi- of both recruitment of the enzymes to specific sub-
tated proteins and again showed a significant Lyn kinase strates and regulation of their intrinsic enzymatic activi-
dependence in the tyrosine phosphorylation and/or as- ties. To investigate the differential recruitment of these
sociation of SHP-2 with the pp130 kDa complex (Figure molecules, we prepared crude membrane and cytosolic
6B). However, unlike SHP-1, tyrosine phosphorylation fractions from Lyn/, Lyn/, and Lynup/up BMMφs and
of SHP-2 was not detected in these cells. Similar results assessed the compartmentalization of each protein.
to those discussed above were also obtained in analy- While Lyn, SIRP, and PIR-B were predominantly local-
ses of PBDMφs (data not shown). ized to the membrane fraction in accordance with their
Others have reported that SHP-1 coimmunoprecipi- intrinsic myristoylation and transmembrane domains,
tates with a complex of 130 kDa phosphoproteins in Mφ respectively, both SHP-1 and SHP-2 were unequally par-
cell lines and BMMφs. Two 130 kDa proteins complexed titioned in the membrane and cytosol in a manner de-
with SHP-1 have been identified as SIRP (SHPS-1) and pendent on the genotype of the cells (Figure 7A). Both
PIR-B (p91; Kubagawa et al., 1997; Timms et al., 1998; SHP-1 and SHP-2 were modestly enriched in the mem-
Veillette et al., 1998; Berg et al., 1998; Blery et al., 1998). brane fraction of Lynup/up cells, and the level of these
Interestingly, both of these molecules are ITIM-con- proteins in the membrane fraction was correspondingly
taining Ig receptor superfamily members with demon- diminished by approximately 50% in Lyn/ cells (Figure
strated signal-inhibitory capacity (Kharitonenkov et al., 7A). In agreement with the enhanced membrane local-
1997; Maeda et al., 1998). The model in which tyrosine ization of SHP-1 and SHP-2, the enzymatic activity of
phosphorylation of the cytoplasmic domains of these these proteins was modestly enhanced in Lynup/up
proteins creates binding sites for the tandem SH2 do- BMMφs (in the case of SHP-1) and correspondingly
mains of SHP-1 and SHP-2 was supported by the finding diminished by approximately 50% in Lyn/ BMMφs (for
that GST-SHP-2/SH2s, but not GST alone, precipitated both SHP-1 and SHP-2) relative to Lyn/ controls (Fig-
the pp130 kDa complex from Lynup/up BMMφs (Figure ure 7B). Thus, the Lyn kinase represents a critical inter-
6C). Again, the ability of the tandem SH2 domains of mediate acting to mobilize the PTPs SHP-1 and SHP-2
SHP-2 to precipitate the pp130 kDa complex was en- to the plasma membrane where they are positioned to
hanced in lysates from Lynup/up cells and reduced in ly- act in establishing signaling thresholds in the myelo-
sates from Lyn/ cells (Figure 6C). Although we cannot monocytic/Mφ lineage (Figure 7C).
rule out the presence of other p130 kDa phosphopro-
teins in SHP-1 and SHP-2 precipitates, both SIRP and Discussion
PIR-B exhibited enhanced tyrosine phosphorylation in
Lynup/up-derived cells and conversely, were hypophos-
In this study, we set out to investigate the role of the
phorylated in Lyn/ BMMφs (Figure 6D). Moreover, the
Lyn kinase in the hematopoietic system using both Lyn
association of SHP-1/2 with PIR-B and SIRP was en-
gain- and loss-of-function mouse models. To our sur-
hanced in Lynup/up-derived BMMφs (Figure 6D and data
prise, mice engineered to express a constitutively acti-not shown).
vated form of Lyn containing a mutation that is onco-Both SIRP and PIR-B were also tyrosine phosphory-
genic in other Src family kinases did not exhibit leukemialated when coexpressed with Lyn in 293T cells, arguing
or tumor development. By contrast, we have shown thatthat both of these ITIM-bearing receptors may be direct
aged Lyn/mice develop severe splenomegaly and dis-substrates of Lyn (Figure 6E). We and others have shown
seminated Mφ tumors. Moreover, transfer of tumor-that CSF-1 activation of c-fms leads to tyrosine phos-
bearing spleen cells from Lyn/ mice leads to the emer-phorylation of SIRP (Figure 6F; Kharitonenkov et al.,
gence of tumors within both primary and secondary1997; Timms et al., 1998). However, the Lyn-dependent
SCID mice. The transplanted cells, like those of the origi-SIRP phosphorylation observed in BMMφs was un-
nal mouse donors, are often widely disseminatedchanged in both CSF-1-stimulated and -starved cells
throughout the SCID mice and show a collection of fea-(data not shown). Lyn-dependent tyrosine phosphoryla-
tures consistent with their Mφ classification. The findingtion of SIRP and PIR-B in 293T cells resulted in their
that mice lacking Lyn are prone to myeloid expansionassociation with either SHP-1 or SHP-2 (Figures 6F and
and tumor development is intriguing. Indeed, in that Src6G). However, this was not the case for SHIP-1, as al-
family kinases have long been considered as protoonco-though Lyn expression led to the tyrosine phosphoryla-
genes, it would seem counterintuitive that Lyn-deficienttion of SHIP-1, SIRP, and PIR-B, we were unable to
mice develop tumors, whereas Lynup/up mutant mice aredetect either SIRP or PIR-B in SHIP-1 precipitates from
viable and superficially healthy with no propensity to-BMMφ or 293T cell lysates (data not shown). The Lyn-
ward tumor development.dependent enhancement of tyrosine phosphorylation of
In younger Lyn/ mice, a myeloproliferative syndromeboth SHP-1 and SHIP-1 in Lyn/up and Lynup/up-derived
is apparent with significant increases in myeloid progen-BMMφs, and the reduction in such phosphorylation in
itors in spleen and peripheral blood. This phenotypeLyn-deficient cells, suggests that Lyn is critically in-
is a consistent feature of all Lyn/ mice analyzed. Involved in the membrane recruitment, intrinsic level of
agreement with the enhanced myelopoiesis in Lyn/tyrosine phosphorylation, and the phosphorylation-
associated enzymatic activity of these proteins. mice, flow cytometric analyses showed that large num-
Immunity
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Figure 7. Lyn-Dependent Activation and
Membrane Localization of SHP-1 and SHP-2
(A) BMMφ cytosolic and membrane fractions
were blotted with anti-Lyn (panel 1), anti-
PIR-B (panel 2), anti-SIRP (panel 3), anti-
SHP-1 (panel 4), or anti-SHP-2 (panel 5) Abs.
Relative quantities of SHP-1 and SHP-2 in
each fraction were determined by densitome-
try and are shown above each panel.
(B) SHP-1 and SHP-2 were precipitated from
BMMφ lysates and subjected to immune
complex PTP assays in the presence of Src
Y416 phosphopeptide. Each point represents
the mean and SD from two separate experi-
ments.
(C) Model for Lyn-dependent mobilization of
SHP-1 and SHP-2 to the plasma membrane
in BMMφs.
bers of Mφs and neutrophils were found in the spleens pathways that may be aberrantly regulated and thus be
potential predisposing elements in a pathway leadingof younger Lyn/ mice. Tumor development in Lyn/
mice has a relatively long latency (usually 30 weeks), to tumor development in Lyn/ mice. We have provided
evidence that SHP-1 and SHIP-1 are differentially tyro-suggesting that the myeloid expansion may become
malignant due to additional acquired mutations within sine phosphorylated, and that SIRP and PIR-B are dif-
ferentially associated with SHP-1 and SHP-2 in a manneran expanded population of myeloid progenitors.
The splenomegaly and EMH characteristic of the dependent on the activity of Lyn in the various mouse
mutants. SIRP has been previously identified as a tar-Lyn/ phenotype is similar to, although less severe than,
that present in Mev/Mev and SHIP-1/ mice. To date, get of receptor tyrosine kinases and Src family kinases
in vitro, and is also tyrosine phosphorylated in responsewe have not seen any reports of either SHIP-1 or SHP-1
loss-of-function mutant mice exhibiting myeloid tumor to cell adhesion signals (Fujioka et al., 1996; Kharitonen-
kov et al., 1997; Tsuda et al., 1998; Timms et al., 1999).susceptibility. Although SHIP-1/ mice do develop ac-
cumulations of myeloid cells in kidney, lung, and liver, Importantly, expression of SIRP has been demon-
strated in BM progenitors, raising the possibility thatthe transplantability of this population has not been re-
ported. Additionally, whereas the myeloid populations Lyn-dependent mobilization of SH2-containing phos-
phatases such as SHP-1 and SHP-2 to SIRP may bein SHIP-1/ mice show characteristics typical of mono-
cytes/Mφs and granulocytes, tumors in Lyn/ mice are important in signal inhibition within these cells (Seiffert
et al., 1999). Moreover, reduced levels of SIRP expres-composed of Mφs. Both Mev/Mev and SHIP-1/ mice
exhibit consolidation of the lungs with myeloid cell infil- sion are observed in a large fraction of human myeloid
leukemias (Seiffert et al., 1999), and SIRP expressiontrates leading to the death of 50% of SHIP-1/ mice
by 12 weeks of age (Helgason et al., 1998; Liu et al., potently antagonizes v-fms transformation of fibroblasts
(Kharitonenkov et al., 1997). However, the possibility1999) and the death of all Mev/Mev mice by 6–8 weeks
(Shultz et al., 1984). By contrast, Lyn/ mice rarely ex- that defective SIRP-dependent signal inhibition in the
presence of CD47, the ubiquitously expressed ligand ofhibit severe myeloid cell lung infiltrates. The severity of
this lung pathology in Mev/Mev and SHIP-1/ mice may SIRP, is responsible for deregulated myelopoiesis in
Lyn/ mice remains to be evaluated (Jiang et al., 1999).well preclude observing age-dependent macrophage
tumor development in these strains. However, heterozy- Less is known about the role of PIR-B in signal trans-
duction, except that it is a substrate of Lyn in DT40 Bgous Me/ mice have been reported to exhibit an in-
creased incidence of lymphoma (Shultz et al., 1993; Big- cell lines and is constitutively tyrosine-phosphorylated
and associated with Lyn in primary splenocytes (Maedanon and Siminovitch, 1994).
In this study, we analyzed both peripheral blood and et al., 1998; Blery et al., 1998; Ho et al., 1999). Although
it is unclear what the physiological ligand for PIR-B mayBMMφs from both Lyn loss- and gain-of-function mu-
tant mice to investigate the Lyn substrates and signaling be, the wide distribution of Ig superfamily ITIM-bearing
A Role for the Lyn Kinase in Tumor Suppression
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to introduce the LynY508F mutation and a unique XbaI restriction sitereceptors such as PIR-B and SIRP suggest a role in
immediately 3 of the stop codon to subclone the XbaI-NheI pro-tempering signal transduction signals in response to a
moter-less IRES neomycin cassette (from P. Mountford). Two ho-vast array of stimuli (reviewed in Ravetch and Lanier,
mologous recombinant W9.5 ES cell lines were used to generate
2000). The evidence suggesting that lack of appropriate chimeras capable of transmitting the modified locus through the
tyrosine phosphorylation of SIRP or PIR-B is specifi- germline. Mice carrying the LynY508F point mutation were identified by
PCR, confirmed by Southern blot, and bred to generate homozygouscally linked to the phenotype we have described is pres-
mice. Two independent strains of mice carrying the activating Y508Fently only correlative. Indeed, it is likely that other ITIM-
mutation in the lyn gene have been generated and analyzed. Lyn/bearing receptors and Lyn substrates involved in signal
mice have been described (Hibbs et al., 1995a). MT/MT miceinhibition may also be deregulated in Lyn/ mice. Thus,
(Kitamura and Rajewsky, 1992) were provided by D.M. Tarlinton
the relative contributions of diminished recruitment (Walter and Eliza Hall Institute, Melbourne, Australia) and were
and/or activation of SHP-1, SHP-2, and SHIP-1 to tumor crossed with Lyn/ mice to create double deficient mice. Mice were
housed in microisolation units.development in Lyn/ mice will require further investiga-
tion. In this regard, previous studies have illustrated a
Cells, Cell Culture, and BMMφ Cell Growth and Survival Assayscritical role for Lyn in B lymphocytes. Lyn/ B cells lack
BMMφs were derived from cells extruded from the femurs of 8- tothe full extent of the inhibitory consequences of Lyn-
12-week-old mice. Cells were flushed into DMEM supplementeddependent tyrosine phosphorylation of ITIM motifs in
with 15% heat-inactivated FCS (CSL), 20% L cell-conditioned media
CD22, FcRIIB, and PIR-B, which results in a failure to (LCM), 0.075% sodium bicarbonate, 50 IU/ml penicillin G, 50 g/ml
recruit SHP-1, SHP-2, or SHIP-1 into the BCR complex. streptomycin sulfate, 2 mM Glutamax-1 (Gibco-BRL, Life Technolo-
However, again, the relationship between the lack of gies), and propagated in the above media at 37C with 10% CO2.
Nonadherent cells were removed 24 to 48 hr later and transferredphosphorylation of these individual ITIM-containing re-
into new flasks. Cells were supplemented with LCM every third day.ceptors and other Lyn substrate ITIM-bearing receptors
BMMφs were used on days 5 to 7. For BMMφ proliferation/survivalsuch as CD5, CD72, CD66a, ILT2, -3, -4, -5, LIR8, and
assays, day 5 to 7 cells were scraped from their dishes and plated
PD-1, and the predisposition to autoimmunity in Lyn/ in flat bottom 96-well plates at 5–10,000 cells/well in triplicate. Cells
mice remains to be firmly established (reviewed in Ra- were grown in various concentrations of CSF-1 or GM-CSF for 3 to
vetch and Lanier, 2000). 5 days, and viable cells were stained with MTT as described (Harder
et al., 1998). In experiments where pervanadate was used to inhibitThese studies of Lyn mutant mice demonstrate that
in vivo PTP activity, sodium orthovanadate was dissolved in dH20a significant proportion of SHP-1, SHIP-1, PIR-B, and
to 100 mM. H2O2 (2 mM) was added to this 1000 stock solution,SIRP tyrosine phosphorylation is regulated by Lyn in
and the solution was left at room temperature for 30 min before
primary Mφs. Indeed, the use of the Lynup mouse to filter sterilization and storage at 20C. 293T cells were transiently
explore potential Lyn substrates has illustrated its utility transfected with Superfect reagent (Qiagen) according to the manu-
as a model system in this regard. Our demonstration facturer’s instructions. Plasmids encoding SIRP (T. Matozaki, Kobe
University, Japan), mPIR-B (T. Takai, Tohoku University, Japan),that PTP activity may effectively compensate for the
mLyn wild-type or mLynY508F, c-fms (D. Marks, Royal Melbourne Hos-increased activity of the Lynup kinase mutant also illus-
pital, Australia), and SHP-1 (M. Thomas, Washington University, St.trates potential modes of regulation, which may be lost
Louis) were used.
in the process of oncogenesis. Recent work has demon-
strated a role for CD45 in inhibition of tumorigenesis in Cell Lysis, Immunoblotting, and Immunoprecipitation
low copy number p56lckY505F transgenic mice (Baker et Cells were lysed on ice in buffer containing 1% Triton X-100, 0.1%
al., 2000). We are investigating which PTP(s) might be SDS, 1% glycerol, 50 mM Tris (pH 7.5), 150 mM NaCl, 2 mM EDTA,
1 mM sodium orthovanadate, 50 mM sodium fluoride, 1 mM pef-involved in antagonizing Lyn activity. Others have shown
abloc, and 1 mM aprotinin. Protein concentrations were estimatedthat in BMMφs lacking CD45, both Lyn and Hck exhibit
using the BCA assay (Pierce). Abs used included anti-PY (4G10;enhanced kinase activity (Roach et al., 1997; Katagiri et
UBI), anti-SIRP (UBI), anti-PIR-B (from L. Rohrschneider, Fred
al., 1995, 1999). Our preliminary data suggest that SHP-1 Hutchinson Cancer Research Center and T. Takai, Tohoku Univer-
may be involved in the inhibition of Lyn activity (data sity, Japan), anti-Lyn and anti-SHP-2 (Santa Cruz Biotechnologies),
not shown), an interaction supported by recent studies anti-Hck (from C. Lowell, University of California at San Francisco),
and anti-SHP-1 (from H.-C. Cheng, University of Melbourne, Austra-of Motheaten B cells and cell lines (Yang et al., 1998;
lia). In experiments requiring membrane/cytosol fractionationSomani et al., 2000). This suggests that Lyn is both an
(Ramsby and Makowski, 1999), equal numbers of adherent BMMφsactivator of SHP-1 and a substrate of SHP-1-dependent
were extracted with digitonin buffer (0.01% digitonin, 10 mM HEPES
negative regulation. Assessment of compound Lynup/up [pH 6.8], 300 mM sucrose, 100 mM NaCl, 5 mM EDTA, 3 mM MgCl2,
Mev/Mev (or /Mev) mice will clarify this hypothesis. In 1 mM sodium orthovanadate, and protease inhibitors) for 10 to 20
light of the enhanced activation of signal-inhibitory mol- min. The adherent monolayer was then quickly rinsed in ice-cold
PBS containing 1 mM vanadate before further extraction for 30 minecules such as SHP-1 and SHIP-1 in Lynup/up mice, it will
with Triton X-100 buffer (0.5% Triton X-100, 10 mM HEPES [pH 7.4],also be interesting to explore whether Lynup mice are less
300 mM sucrose, 100 mM NaCl, 3 mM MgCl2, 3 mM EDTA, 1 mMsusceptible to tumor formation induced by oncogenes
sodium orthovanadate, and protease inhibitors). Blots were devel-
such as Bcr-Abl. The possibility that Lyn kinase loss- oped with horseradish peroxidase-linked goat anti-rabbit or sheep
of-function mutations may contribute to human myeloid anti-mouse antiserum and the ECL system (Amersham).
malignancies also warrants further investigation.
Flow Cytometry, Immunohistochemistry, and Histology
Cell preparation and FACS analysis have been described (Hibbs etExperimental Procedures
al., 1995a). Lymphoid organs and tumor masses were embedded
in OCT compound and frozen on dry ice. Cryostat sections (5 M)Mice and Construction of the Lynup (Y508F) Mutant
A targeting vector was constructed using a 5.5 kb genomic fragment were fixed in acetone for 10 min and air dried, and then rehydrated
in PBS for 30 min. Endogenous peroxidase activity was blocked byderived from the 3 end of Lyn14.1, which contains the 3-most
coding exon of the mouse Lyn gene and the C-terminal regulatory incubation with 0.3% H2O2 (in PBS) for 10 min. Slides were washed
in PBS, blocked in 5% FCS/PBS for 30 min before staining with theTyr (Y508) (Hibbs et al., 1995b). Site-directed mutagenesis was used
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mAbs F4/80, Mac1 (M1/70), Gr-1 (Rb6-8C5), B220 (RA3-6B2), Thy-1 tion of p62(DOK) tyrosine phosphorylation in macrophages. J. Biol.
Chem. 274, 35855–35865.(30-H12), or isotype control rat IgG2b, (A95-1) diluted in 5% FCS/
PBS. Sections were then incubated with streptavidin-HRP conjugate Bignon, J.S., and Siminovitch, K.A. (1994). Identification of PTP1C
(DAKO) before development with DAB chromogen solution and mutation as the genetic defect in motheaten and viable motheaten
counterstaining with hematoxylin. For histology, tissues were fixed mice: a step toward defining the roles of protein tyrosine phospha-
for light microscopy in Bouin’s solution for 24 hr before paraffin tases in the regulation of hemopoietic cell differentiation and func-
embedding. Sections were stained with hematoxylin and eosin. tion. Clin. Immunol. Immunopathol. 73, 168–179.
Blery, M., Kubagawa, H., Chen, C.C., Vely, F., Cooper, M.D., and
PTK and PTP Assays
Vivier, E. (1998). The paired Ig-like receptor PIR-B is an inhibitory
PTP activity was detected with the malachite green microtiter plate
receptor that recruits the protein-tyrosine phosphatase SHP-1.
assay as previously described (Harder et al., 1994, 1998). For Lyn
Proc. Natl. Acad. Sci. USA 95, 2446–2451.
kinase enzyme assays, immune complexes were washed exten-
Briggs, S.D., Sharkey, M., Stevenson, M., and Smithgall, T.E. (1997).sively before resuspension in kinase buffer (50 mM Tris [pH 6.8], 50
SH3-mediated Hck tyrosine kinase activation and fibroblast trans-mM NaCl, 0.1% Triton X-100, 10 mM MgCl2, 5 mM MnCl2, 25 M
formation by the Nef protein of HIV-1. J. Biol. Chem. 272, 17899–ATP, 0.5 mM DTT, and 0.1 mM vanadate) containing 10 Ci
17902.[-32P]ATP (3000 Ci/mmole) and 1–3 g of recombinant GST-PTP-
Brown, M.T., and Cooper, J.A. (1996). Regulation, substrates anddomain2 (from F. Jirik, University of British Columbia).
functions of src. Biochim. Biophys. Acta 1287, 121–149.
Progenitor and Apoptosis Assays Brugge, J.S., and Erikson, R.L. (1977). Identification of a transforma-
Progenitor cell numbers were determined in 2 ml semisolid 0.3% tion-specific antigen induced by an avian sarcoma virus. Nature
agar cultures containing 105 spleen cells or 1.5–3.0 l peripheral 269, 346–348.
blood in 35 mm plates. Colony formation was stimulated by the
Chan, V.W., Meng, F., Soriano, P., DeFranco, A.L., and Lowell, C.A.
presence of CSF-1 (10 ng/ml), IL-3 (10 ng/ml), GM-CSF (10 ng/
(1997). Characterization of the B lymphocyte populations in Lyn-
ml), G-CSF (10 ng/ml), or stem cell factor (50 ng/ml). Apoptosis of
deficient mice and the role of Lyn in signal initiation and down-
BMMφs was assessed by FACS. Briefly, treated BMMφs in 24-well
regulation. Immunity 7, 69–81.
plates were rinsed twice in PBS and typsinized for 15 min. Cells
Chan, V.W., Lowell, C.A., and DeFranco, A.L. (1998). Defective nega-and rinse solutions were combined, washed in PBS containing 2%
tive regulation of antigen receptor signaling in Lyn-deficient B lym-FCS, and cells (100 l) were stained by addition of 30 l of a 50
phocytes. Curr. Biol. 8, 545–553.g/ml 7-AAD solution for 30 min. Percentages of apoptotic cells
Chen, H.E., Chang, S., Trub, T., and Neel, B.G. (1996). Regulationwere assessed based on both 7-AAD fluorescence and reduced
of colony-stimulating factor 1 receptor signaling by the SH2 domain-forward scatter criteria.
containing tyrosine phosphatase SHPTP1. Mol. Cell. Biol. 16, 3685–
3697.SCID Mouse Assays
Lyn/ tumor-bearing mouse donors were assessed by palpation. Corey, S.J., and Anderson, S.M. (1999). Src-related protein tyrosine
Spleens exhibiting varying degrees of splenomegaly were removed, kinases in hematopoiesis. Blood 93, 1–14.
passed through a steel mesh, and resuspended in PBS. 107 cells Cornall, R.J., Cyster, J.G., Hibbs, M.L., Dunn, A.R., Otipoby, K.L.,
were injected into the tail vein of 8- to 12-week-old female SCID Clark, E.A., and Goodnow, C.C. (1998). Polygenic autoimmune traits:
mice. Tumors from SCID mice were microdissected and subjected to Lyn, CD22, and SHP-1 are limiting elements of a biochemical path-
PCR analysis with oligonucleotides specific for the Lyn/ mutation. way regulating BCR signaling and selection. Immunity 8, 497–508.
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